fluorouracil has been researched along with Blood Pressure, Low in 15 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial." | 9.14 | Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. ( Ackland, SP; Broad, A; Chua, Y; Cummins, MM; Cunningham, D; Forgeson, G; Ganju, V; Gebski, VJ; Price, TJ; Robinson, B; Saunders, MP; Simes, RJ; Stockler, MR; Tebbutt, NC; van Hazel, GA; Wilson, K; Zalcberg, JR; Zannino, D, 2010) |
| "To determine the plasma pharmacokinetics and the maximum-tolerated dose (MTD) of intravenous (IV) azidothymidine (AZT) administered 90 to 120 minutes after fluorouracil (5-FU) and leucovorin and to preliminarily evaluate the antitumor activity of this combination in metastatic colorectal cancer." | 9.08 | Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients. ( Brunetti, I; Conte, PF; Danesi, R; Dargenio, F; Del Tacca, M; Falcone, A; Nethersell, AB; Pfanner, E, 1996) |
| "Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and 5-fluorouracil (5-FU)." | 7.67 | Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil. ( Jakubowski, AA; Kemeny, N, 1988) |
| "Sixteen patients with metastatic colorectal cancer have been treated with a regimen involving an 120 h continuous infusion of rIL-2, 18 x 10(6) iu m-2 day followed by three injections of 5FU 600 mg m-2 at weekly intervals." | 6.67 | A phase-III study of recombinant interleukin 2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer. ( Franks, CR; Hamblin, TJ; Oskam, R; Palmer, P; Sadullah, S; Stevenson, J; Williamson, P, 1993) |
| "To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial." | 5.14 | Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. ( Ackland, SP; Broad, A; Chua, Y; Cummins, MM; Cunningham, D; Forgeson, G; Ganju, V; Gebski, VJ; Price, TJ; Robinson, B; Saunders, MP; Simes, RJ; Stockler, MR; Tebbutt, NC; van Hazel, GA; Wilson, K; Zalcberg, JR; Zannino, D, 2010) |
| "To determine the plasma pharmacokinetics and the maximum-tolerated dose (MTD) of intravenous (IV) azidothymidine (AZT) administered 90 to 120 minutes after fluorouracil (5-FU) and leucovorin and to preliminarily evaluate the antitumor activity of this combination in metastatic colorectal cancer." | 5.08 | Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients. ( Brunetti, I; Conte, PF; Danesi, R; Dargenio, F; Del Tacca, M; Falcone, A; Nethersell, AB; Pfanner, E, 1996) |
| "Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and 5-fluorouracil (5-FU)." | 3.67 | Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil. ( Jakubowski, AA; Kemeny, N, 1988) |
| "Sixteen patients with metastatic colorectal cancer have been treated with a regimen involving an 120 h continuous infusion of rIL-2, 18 x 10(6) iu m-2 day followed by three injections of 5FU 600 mg m-2 at weekly intervals." | 2.67 | A phase-III study of recombinant interleukin 2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer. ( Franks, CR; Hamblin, TJ; Oskam, R; Palmer, P; Sadullah, S; Stevenson, J; Williamson, P, 1993) |
| "Hypotension was observed in three of five patients at the highest dose level (0." | 2.67 | A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer. ( Botet, J; Crown, J; Gasparetto, C; Gordon, M; Jakubowski, A; Kemeny, N; Meisenberg, B; Sheridan, C; Toner, G; Wong, G, 1991) |
| "Transient hypotension was the most common side effect occurring in association with amifostine." | 1.31 | Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study. ( Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (20.00) | 18.7374 |
| 1990's | 6 (40.00) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 1 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tebbutt, NC | 1 |
| Wilson, K | 1 |
| Gebski, VJ | 1 |
| Cummins, MM | 1 |
| Zannino, D | 1 |
| van Hazel, GA | 1 |
| Robinson, B | 1 |
| Broad, A | 1 |
| Ganju, V | 1 |
| Ackland, SP | 1 |
| Forgeson, G | 1 |
| Cunningham, D | 1 |
| Saunders, MP | 1 |
| Stockler, MR | 1 |
| Chua, Y | 1 |
| Zalcberg, JR | 1 |
| Simes, RJ | 1 |
| Price, TJ | 1 |
| Pérez, J | 1 |
| Rodríguez, MJ | 1 |
| Campaña, O | 1 |
| Veiras, S | 1 |
| Lorenzo, D | 1 |
| Lamas, M | 1 |
| Alvarez, J | 1 |
| Iqbal, K | 1 |
| Chu, Q | 1 |
| Mei, Q | 1 |
| Chen, Y | 1 |
| Niederle, N | 2 |
| Kurschel, E | 1 |
| Schmidt, CG | 1 |
| Bounous, G | 1 |
| O'Shaughnessy, JA | 1 |
| Denicoff, AM | 1 |
| Venzon, DJ | 1 |
| Danforth, D | 1 |
| Pierce, LJ | 1 |
| Frame, JN | 1 |
| Bastian, A | 1 |
| Ghosh, B | 1 |
| Goldspiel, B | 1 |
| Miller, L | 1 |
| Weidmann, B | 1 |
| Teipel, A | 1 |
| Hamblin, TJ | 1 |
| Sadullah, S | 1 |
| Williamson, P | 1 |
| Stevenson, J | 1 |
| Oskam, R | 1 |
| Palmer, P | 1 |
| Franks, CR | 1 |
| Falcone, A | 1 |
| Danesi, R | 1 |
| Dargenio, F | 1 |
| Pfanner, E | 1 |
| Brunetti, I | 1 |
| Del Tacca, M | 1 |
| Nethersell, AB | 1 |
| Conte, PF | 1 |
| Muc, M | 1 |
| Baranowski, M | 1 |
| Braczkowski, R | 1 |
| Zubelewicz, B | 1 |
| Kozowicz, A | 1 |
| Santini, D | 1 |
| Tonini, G | 1 |
| Salerno, A | 1 |
| Vincenzi, B | 1 |
| Patti, G | 1 |
| Battistoni, F | 1 |
| Dicuonzo, G | 1 |
| Labianca, R | 1 |
| Genvresse, I | 1 |
| Lange, C | 1 |
| Schanz, J | 1 |
| Schweigert, M | 1 |
| Harder, H | 1 |
| Possinger, K | 1 |
| Späth-Schwalbe, E | 1 |
| Schüll, B | 1 |
| Kornek, GV | 1 |
| Scheithauer, W | 1 |
| Crown, J | 1 |
| Jakubowski, A | 1 |
| Kemeny, N | 2 |
| Gordon, M | 1 |
| Gasparetto, C | 1 |
| Wong, G | 1 |
| Sheridan, C | 1 |
| Toner, G | 1 |
| Meisenberg, B | 1 |
| Botet, J | 1 |
| Jakubowski, AA | 1 |
6 trials available for fluorouracil and Blood Pressure, Low
| Article | Year |
|---|---|
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
[Biological effect of recombined leukocyte alpha-2-interferon in metastasizing colorectal cancers].
Topics: Adenocarcinoma; Adult; Colonic Neoplasms; Female; Fluorouracil; Herpes Labialis; Humans; Hypotension | 1984 |
A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1994 |
A phase-III study of recombinant interleukin 2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capillary Permeabi | 1993 |
Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore | 1996 |
A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer.
Topics: Adult; Aged; Blood Glucose; Bone Marrow; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combinati | 1991 |
9 other studies available for fluorouracil and Blood Pressure, Low
| Article | Year |
|---|---|
[Anesthetic management for scheduled peritonectomy and hyperthermic intraperitoneal chemotherapy in 20 patients].
Topics: Adult; Aged; Analgesia, Epidural; Anesthesia, General; Anesthesia, Inhalation; Anesthesia, Intraveno | 2006 |
Bevacizumab-associated reversible hypotension.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2007 |
Protection of the gastrointestinal mucosa by elemental diets.
Topics: Animals; Fluorouracil; Food, Formulated; Humans; Hypotension; Intestinal Mucosa; Radiation Injuries; | 1980 |
The syndrome of 5-fluorouracil cardiotoxicity: an elusive cardiopathy.
Topics: Adenocarcinoma; Angina Pectoris; Electrocardiography; Female; Fluorouracil; Heart; Heart Diseases; H | 1994 |
[Cardiotoxic effect of the herec-TNF alpha preparation given intravenously to patients with advanced neoplasms].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Female; Fluoroura | 1996 |
Idiosyncratic reaction after oxaliplatin infusion.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chills; Fever; Fluorouracil; | 2001 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Com | 2001 |
Idiosyncratic reaction after oxaliplatin: circumvention by use of a continuous infusional administration schedule.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colo | 2001 |
Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil.
Topics: Adult; Cisplatin; Colonic Neoplasms; Echocardiography; Electrocardiography; Female; Fluorouracil; He | 1988 |